Further findings were that the UACR increased between stage 0 and stages 1–2 of HepFe; patients with higher levels of HepFe showed higher levels of NAFLD, serum ferritin, and HOMA-IR; and, finally, patients in stage 2 and 3 of NAFLD showed higher levels of SBP, insulin, HOMA-IR, and HepFe, as compared to patients in stage 1. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.